These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 37189724)

  • 21. Antivirals against Monkeypox (Mpox) in Humans: An Updated Narrative Review.
    Bruno G; Buccoliero GB
    Life (Basel); 2023 Sep; 13(10):. PubMed ID: 37895350
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral Brincidofovir Therapy for Monkeypox Outbreak: A Focused Review on the Therapeutic Potential, Clinical Studies, Patent Literature, and Prospects.
    Imran M; Alshammari MK; Arora MK; Dubey AK; Das SS; Kamal M; Alqahtani ASA; Sahloly MAY; Alshammari AH; Alhomam HM; Mahzari AM; Abida ; Rabaan AA; Dzinamarira T
    Biomedicines; 2023 Jan; 11(2):. PubMed ID: 36830816
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ocular manifestations of mpox.
    Nguyen M; Doan T; Seitzman GD
    Curr Opin Ophthalmol; 2024 Jun; ():. PubMed ID: 38847744
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Challenges in Managing Treatment-Resistant Mpox Complicated by Severe Superinfection.
    Fortier JC; Marsalisi C; Cordova E; Guo HJ; Verdecia J
    Open Forum Infect Dis; 2024 Apr; 11(4):ofae138. PubMed ID: 38651138
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of interventional clinical trials for monkeypox; systematic review of ClinicalTrials.gov database.
    Alorfi NM; Alshehri FS; Haseeb A
    Front Public Health; 2023; 11():1144325. PubMed ID: 36969617
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of tecovirimat in subjects with Mpox.
    Tempestilli M; Mondi A; D'Avolio A; Forini O; Pinnetti C; Mazzotta V; Gagliardini R; Beccacece A; De Nicolò A; Faccendini P; Cimini E; Maggi F; Girardi E; Nicastri E; Boffito M; Vaia F; Antinori A
    Int J Antimicrob Agents; 2024 Feb; 63(2):107068. PubMed ID: 38141836
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Repositioning potentials of smallpox vaccines and antiviral agents in monkeypox outbreak: A rapid review on comparative benefits and risks.
    Islam MR; Hossain MJ; Roy A; Hasan AHMN; Rahman MA; Shahriar M; Bhuiyan MA
    Health Sci Rep; 2022 Sep; 5(5):e798. PubMed ID: 36032515
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In silico identification of potential phytochemical inhibitors for mpox virus: molecular docking, MD simulation, and ADMET studies.
    Ghate SD; Pinto L; Alva S; Srinivasa MG; Vangala RK; Naik P; Revanasiddappa BC; Rao RSP
    Mol Divers; 2024 Mar; ():. PubMed ID: 38519803
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of core therapeutic targets for Monkeypox virus and repurposing potential of drugs against them: An in silico approach.
    Sahu A; Gaur M; Mahanandia NC; Subudhi E; Swain RP; Subudhi BB
    Comput Biol Med; 2023 Jul; 161():106971. PubMed ID: 37211001
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The global patent landscape of emerging infectious disease monkeypox.
    Cai Y; Zhang X; Zhang K; Liang J; Wang P; Cong J; Xu X; Li M; Liu K; Wei B
    BMC Infect Dis; 2024 Apr; 24(1):403. PubMed ID: 38622539
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluating the Immunogenicity and Safety of a Smallpox Vaccine to Monkeypox in Healthy Japanese Adults: A Single-Arm Study.
    Tomita N; Morino E; Terada-Hirashima J; Uemura Y; Shimizu Y; Saito S; Suzuki T; Okumura N; Iwasaki H; Ebihara H; Shimojima M; Sugiura W; Ohmagari N; Ujiie M
    Life (Basel); 2023 Mar; 13(3):. PubMed ID: 36983942
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monkeypox and drug repurposing: seven potential antivirals to combat the viral disease.
    Varghese R; Patel P; Kumar D; Sharma R
    Rev Environ Health; 2023 Feb; ():. PubMed ID: 36809250
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monkeypox (mpox) virus: Classification, origin, transmission, genome organization, antiviral drugs, and molecular diagnosis.
    Karagoz A; Tombuloglu H; Alsaeed M; Tombuloglu G; AlRubaish AA; Mahmoud A; Smajlović S; Ćordić S; Rabaan AA; Alsuhaimi E
    J Infect Public Health; 2023 Apr; 16(4):531-541. PubMed ID: 36801633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of tecovirimat on healing time and viral clearance by emulation of a target trial in patients hospitalized for mpox.
    Mazzotta V; Cozzi-Lepri A; Lanini S; Mondi A; Carletti F; Tavelli A; Gagliardini R; Vita S; Pinnetti C; Aguglia C; Colavita F; Faccendini P; Matusali G; Faraglia F; Beccacece A; Paulicelli J; Girardi E; Nicastri E; Vaia F; Maggi F; Antinori A
    J Med Virol; 2023 Jun; 95(6):e28868. PubMed ID: 37306318
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The
    Jalilian S; Bastani MN
    Iran J Microbiol; 2022 Dec; 14(6):770-777. PubMed ID: 36721442
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The use of antivirals in the treatment of human monkeypox outbreaks: a systematic review.
    Shamim MA; Padhi BK; Satapathy P; Veeramachaneni SD; Chatterjee C; Tripathy S; Akhtar N; Pradhan A; Dwivedi P; Mohanty A; Rodriguez-Morales AJ; Sah R; Al-Tammemi AB; Al-Tawfiq JA; Nowrouzi-Kia B; Chattu VK
    Int J Infect Dis; 2023 Feb; 127():150-161. PubMed ID: 36470502
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Severe Mpox Among People With Advanced Human Immunodeficiency Virus Receiving Prolonged Tecovirimat in New York City.
    Garcia EA; Foote MMK; McPherson TD; Lash MK; Bosompem AN; Bouscaren A; Chan J; DiLorenzo MA; Feihel D; Fowler RC; Gandhi V; Jenny-Avital ER; Kopping EJ; Mazo D; McLean J; Mgbako O; Sayegh MN; Shaw RN; Su M; Meissner JS; Wang JC; Wen W; Winters JC; Zeana CB; Zucker J; Wong M
    Open Forum Infect Dis; 2024 Jun; 11(6):ofae294. PubMed ID: 38868307
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Viral genomic features predict orthopoxvirus reservoir hosts.
    Tseng KK; Koehler H; Becker DJ; Gibb R; Carlson CJ; Fernandez MDP; Seifert SN
    bioRxiv; 2023 Oct; ():. PubMed ID: 37961540
    [No Abstract]   [Full Text] [Related]  

  • 39. Clinical Characteristics and Outcomes of Patients With Mpox Who Received Tecovirimat in a New York City Health System.
    Vo C; Zomorodi R; Silvera R; Bartram L; Lugo LA; Kojic E; Urbina A; Aberg J; Sigel K; Chasan R; Patel G
    Open Forum Infect Dis; 2023 Nov; 10(11):ofad552. PubMed ID: 38023539
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Application of Artificial Intelligence Techniques for Monkeypox: A Systematic Review.
    Chadaga K; Prabhu S; Sampathila N; Nireshwalya S; Katta SS; Tan RS; Acharya UR
    Diagnostics (Basel); 2023 Feb; 13(5):. PubMed ID: 36899968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.